Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera

Vertex Pharmaceuticals is best known for its cystic fibrosis franchise. But over the past several years Vertex has been making inroads elsewhere, and a deal it is announcing this morning continues that strategy.

Vertex (NASDAQ: VRTX), of Boston, will pay privately held startup Kymera Therapeutics $70 million to form an alliance to develop a group of drugs for “serious specialty diseases.” Vertex won’t say which ones, but beyond cystic fibrosis (CF), where it has three FDA-approved drugs that generated $3 billion in sales last year, the company has largely been focusing on rare diseases that are caused by easily identifiable... Read more »

Reprints | Share:          E-mail




Tags: Deals, Startups, Boston, Trends, Vc, Fda, GlaxoSmithKline, Biotech, Pain, Cystic Fibrosis, Life Sciences, CRISPR Therapeutics, Vertex, Merck KGaA, Hepatitis C, Vertex Pharmaceuticals, National blog main, Boston blog main, Boston top stories, Nurix, Sickle Cell Disease, C4 Therapeutics, Vertex Nasdaq, Arbor Biotechnologies, Beta-Thalassemia, Kymera Therapeutics, Arvinas, Cedilla Therapeutics, Protein Degradation, Jeff Leiden, Focal Segmental Glomerulosclerosis, Genomics plc, X-Chem